Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, March 20, 2015, 84 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $473.57 to $48,050,000.00.

Highlighted Stocks Traded by Insiders:

Willis Lease Finance (WLFC) - FREE Research Report

Nunemaker Donald A, who is President at Willis Lease Finance, sold 7,722 shares at $19.31 on March 20, 2015. Following this transaction, the President owned 93,266 shares meaning that the stake was reduced by 7.65% with the 7,722-share transaction.

Morris Robert T, who is Director at Willis Lease Finance, sold 2,500 shares at $19.30 on March 20, 2015. Following this transaction, the Director owned 6,459 shares meaning that the stake was reduced by 27.9% with the 2,500-share transaction.

The shares most recently traded at $18.37, down $0.93, or 5.07% since the insider transaction. Historical insider transactions for Willis Lease Finance go as follows:

  • 4-Week # shares bought: 891
  • 4-Week # shares sold: 6,678
  • 12-Week # shares bought: 891
  • 12-Week # shares sold: 6,678
  • 24-Week # shares bought: 891
  • 24-Week # shares sold: 32,963

The average volume for Willis Lease Finance has been 10,000 shares per day over the past 30 days. Willis Lease Finance has a market cap of $159.8 million and is part of the services sector and diversified services industry. Shares are down 13.06% year-to-date as of the close of trading on Friday.

Willis Lease Finance Corporation is engaged in leasing commercial aircraft engines and equipment worldwide. The company leases commercial aircraft engines and other aircraft-related equipment to air carriers, manufacturers, and overhaul/repair facilities. The company has a P/E ratio of 21.6. Currently, there are no analysts who rate Willis Lease Finance a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on WLFC - FREE

TheStreet Quant Ratings rates Willis Lease Finance as a hold. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, deteriorating net income and generally higher debt management risk. Get the full Willis Lease Finance Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Globus Medical (GMED) - FREE Research Report

Paul David C, who is Chief Executive Officer at Globus Medical, sold 1.9 million shares at $25.00 on March 20, 2015. Following this transaction, the Chief Executive Officer owned 1.1 million shares meaning that the stake was reduced by 64.07% with the 1.9 million-share transaction.

The shares most recently traded at $24.37, down $0.63, or 2.59% since the insider transaction. Historical insider transactions for Globus Medical go as follows:

  • 4-Week # shares sold: 32,510
  • 12-Week # shares sold: 32,510
  • 24-Week # shares sold: 32,510

The average volume for Globus Medical has been 374,100 shares per day over the past 30 days. Globus Medical has a market cap of $1.8 billion and is part of the health care sector and health services industry. Shares are up 3.53% year-to-date as of the close of trading on Friday.

Globus Medical, Inc., a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. It offers products that address an array of spinal pathologies, anatomies, and surgical approaches. The company has a P/E ratio of 25.9. Currently, there are 10 analysts who rate Globus Medical a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GMED - FREE

TheStreet Quant Ratings rates Globus Medical as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Globus Medical Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Provident Financial Holdings (PROV) - FREE Research Report

Gale Richard L, who is Senior Vice President at Provident Financial Holdings, sold 29 shares at $16.33 on March 20, 2015. Following this transaction, the Senior Vice President owned 101,397 shares meaning that the stake was reduced by 0.03% with the 29-share transaction.

The shares most recently traded at $16.16, down $0.17, or 1.05% since the insider transaction. Historical insider transactions for Provident Financial Holdings go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Provident Financial Holdings has been 16,500 shares per day over the past 30 days. Provident Financial Holdings has a market cap of $146.0 million and is part of the financial sector and banking industry. Shares are up 2.84% year-to-date as of the close of trading on Friday.

Provident Financial Holdings, Inc. operates as the holding company for Provident Savings Bank, F.S.B. that provides community and mortgage banking services to consumers and small to mid-sized businesses in the Inland Empire region of Southern California. The stock currently has a dividend yield of 2.71%. The company has a P/E ratio of 19.1. Currently, there is 1 analyst who rates Provident Financial Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on PROV - FREE

TheStreet Quant Ratings rates Provident Financial Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, attractive valuation levels, growth in earnings per share, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Provident Financial Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null